InvestorsHub Logo
Followers 0
Posts 53
Boards Moderated 0
Alias Born 03/29/2009

Re: tzm post# 1895

Saturday, 05/23/2009 6:10:08 AM

Saturday, May 23, 2009 6:10:08 AM

Post# of 2070
DVAX makes HEPLISAV, a Phase 3 clinical stage product for the treatment of hepatitis B vaccine. Recently they presented preclinical data from its Novel Universal Flu vaccine.
With 47.19M Market Cap, the stock looks attractive, if FDA will lift the hold on HEPLISAV at the next meeting, it could soar. HEPLISAV could substitute ENGERIX as standard in the cure of hepatitis B.